Otsuka Holdings Co., Ltd.4578
▲ PositiveCapitalrelevance
Raised full-year profit forecast and increased dividend, driven by strong Rexulti sales and cost optimization.
Impact on stocks 1
Biotech & Genomic Medicine
Otsuka Holdings Co., Ltd.Otsuka Holdings has revised upward its full-year earnings forecast for the fiscal year ending December 2026. The company raised its operating profit forecast by 30.3 percent from the previous projection to 469 billion yen, and its profit attributable to owners of the parent by 34.0 percent to 355 billion yen. It also plans to increase the annual dividend to 200 yen this fiscal year, up from 140 yen in the previous year. In the first half, revenue rose 12.8 percent year on year to 1.3323 trillion yen, operating profit increased 15.0 percent to 278.5 billion yen, and profit attributable to owners of the parent grew 24.3 percent to 215.6 billion yen, marking higher revenue and profit. The upward revision was supported by strong sales of its main antipsychotic drug Rexulti and an improved selling, general and administrative expense ratio due to cost optimization. The share price climbed further after the earnings release and has risen about 10 percent over the past month.
Otsuka Holdings Co., Ltd.Raised full-year profit forecast and increased dividend, driven by strong Rexulti sales and cost optimization.